Meta-analysis of predictive models to assess the clinical validity and utility for patient-centered medical decision making: application to the CAncer of the Prostate Risk Assessment (CAPRA)

Table 4 Investigation of the heterogeneity of the HRs according to CAPRA-based strata

	Number of studies per subgroup	Pooled HR (High versus Low) per subgroup	p-value	Pooled HR (Intermediate versus Low) per subgroup	p-value
Effective size	> 1000: 5 ≤ 1000: 4	14.60 [7.24–29.43] 8.13 [4.13–16.01]	0.240	4.45 [2.32–8.54] 2.35 [1.59–3.47]	0.098
Inclusion period	Inclusion start ≥1999: 3 Inclusion start < 1999: 6	10.37 [5.00–21.49] 11.78 [5.83–23.80]	0.804	2.78 [1.83–4.24] 3.78 [2.04–7.00]	0.419
Geographic origin	American: 4 Other: 5	13.37 [9.25–19.32] 9.75 [4.02–23.60]	0.518	3.34 [2.41–4.61] 3.39 [1.48–7.77]	0.971

ISSN: 1472-6947